Explores the complexity of cancer, challenges in research translation, and the applications of tissue engineering for cancer models and drug screening.
Explores the selection and rationale of preclinical animal models in drug development, emphasizing the 10 to 15-year path to a marketed small-molecule drug.
Delves into the molecular basis of genetic diseases, discussing specific examples like Phenylketonuria and Haemophilia A, and the development of small molecule drugs for genetic disorders.
Explores the importance of protein-ligand interactions, focusing on binding affinities and energetic landscapes, with implications for drug development and specificity.
Explores quantitative proteome profiling for drug target identification through activity-based protein profiling and advanced mass spectrometry techniques.
Explores small molecule drugs for infectious diseases, covering global mortality rates, viral and bacterial injuries, antiviral and antibacterial agents, and the development of COX2 inhibitors.
